Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Heron Therapeutics (NASDAQ: HRTX) saw its shares rise 14.9% this week. The stock, which closed at $8.68 last Friday, climbed to as high as $9.97 on Thursday. The stock is still down more than 54% for the year and is closer to its 52-week low of $8.29 than its high of $22.40. Ima...
Short squeezes can deliver enormous returns for investors in the blink of an eye. Several so-called "meme stocks" generated jaw-dropping gains for investors earlier this year due to this phenomenon. The mechanics of a short squeeze are fairly straightforward. Short-sellers, or inves...
Ensysce Biosciences (NASDAQ:ENSC) +83%. Inspira Technologies (NASDAQ:IINN) +59%. American Virtual Cloud Technologies (NASDAQ:AVCT) +29% announces significant projected revenue growth of Kandy, its cloud communications platform. Siyata Mobile (NASDAQ:SYTA) +28%. Digital Brands (NASDAQ:DBG...
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF® - Approval provides a significantly broader indication for ZYNRELEF, now covering approximately 7 million procedures a year - - Conference call and webcast today, December 9, 2...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Heron Therapeutics (NASDAQ:HRTX) announces the submission of its New Drug Application (NDA) to the FDA for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults. The NDA filing includes data demonstrating the bioequivalence of HTX-01...
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA PR Newswire SAN DIEGO , Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focu...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...